MinorDirect oral anticoagulants (factor Xa inhibitors)×Benzamide prokinetic with combined serotonin and dopamine receptor activity
Updated · Methodology
Mechanism
CYP3A4/5 is the main enzyme that metabolises apixaban in the liver, and apixaban is also a substrate of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.2). In vitro data show that the same CYP3A4 is the main enzyme that metabolises cinitapride, with a smaller role for CYP2C8. Drugs that markedly inhibit CYP3A4 can change its pharmacokinetics (cinitapride SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.5 and 5.2). In vitro, apixaban inhibited neither CYP3A4 nor CYP2C8, so it is not expected to change the elimination of such drugs (apixaban SmPC, EMA, section 4.5). Cinitapride speeds up gastric emptying and may alter the absorption of some drugs. Its SmPC does not name apixaban, and the apixaban documents say nothing about the effect of gastric emptying on apixaban absorption (cinitapride SmPC, AEMPS, section 4.5; apixaban SmPC, EMA, section 5.2). The documents do not address this combination.
Symptoms
The documents describe no symptoms linked to this combination. The main risk of apixaban is bleeding: bleeding, bruising, nosebleeds and haematomas are common (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8). Severe bleeding can be fatal (apixaban label, US Food and Drug Administration, FDA, section 5.2). Cinitapride uncommonly causes drowsiness. Extrapyramidal reactions with spasms of the face, neck and tongue muscles, rash, itching, angioedema, breast enlargement and galactorrhoea are possible, and in older people on long-term treatment tardive dyskinesia can develop (cinitapride SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4 and 4.8).
Management
According to the documents, the combination is acceptable, and the doses of apixaban and cinitapride need no change. Cinitapride is not among the drugs that the apixaban SmPC lists for cautious use or advises against combining with apixaban (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5). Apixaban is not among the drugs named in the cinitapride SmPC (cinitapride SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Adults over 20 years take cinitapride 1 mg three times a day, 15 minutes before meals, and there is no point in increasing the recommended dose (cinitapride SmPC, AEMPS, section 4.2). Apixaban can be taken with or without food (apixaban SmPC, EMA, section 5.2). Cinitapride is not prescribed when stimulating gastric motility could be harmful because of bleeding, obstruction or perforation (cinitapride SmPC, AEMPS, section 4.3). People taking apixaban are monitored closely for signs of bleeding, and apixaban is stopped if severe bleeding occurs (apixaban SmPC, EMA, section 4.4). Patients are told the signs of blood loss and asked to go to an emergency department without delay if these signs appear (apixaban label, US Food and Drug Administration, FDA, section 5.2).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- FDA: Eliquis (apixaban) prescribing information (2025)– FDA, DailyMed, Eliquis, E.R. Squibb & Sons, setid e9481622-7cc6-418a-acb6-c5450daae9b0, revisión 04/2025, secciones 4 y 7.1
- AEMPS: Ficha técnica: Cinitaprida, Cidine 1 mg comprimidos (nº registro 58459), sección 4.5 (2020)– AEMPS, CIMA, nº registro 58459 (Almirall), revisión 03/2020 (fecha de revisión del texto 03/2019), secciones 4.2, 4.3, 4.5 y 5.2